BPC-157 consistently shows positive effects on tissue healing in animal models, but there are virtually no controlled studies in humans. Almost nothing has been established regarding safety, dosage and indications in humans. Use outside regular frameworks carries real risks of uncertainty.
BPC-157 is a synthetic pentadecapeptide (a chain of fifteen amino acids) originally derived from a protein found in gastric juice. In animal models, primarily in rodents, it consistently shows positive effects on the recovery of tendons, ligaments and skeletal muscle following injury. In gastrointestinal conditions as well, ranging from the oesophagus to the intestines, BPC-157 proved more effective than standard growth factors such as EGF and VEGF in animal studies. This makes it preclinically promising (PMID 30915550, 29998800).
At the cellular level, BPC-157 promotes the outgrowth of tendon tissue cells, protects cells against oxidative stress and stimulates cell migration. This is thought to occur via the so-called FAK-paxillin signalling pathway, a pathway involved in how cells attach and move (PMID 21030672). In addition, preclinical research describes it as a potent stimulator of new blood vessel formation through multiple routes, including NO, VEGF and FAK (PMID 23782145).
The problem is the enormous gap between animals and humans. No controlled clinical studies in humans exist that support the efficacy of BPC-157 in orthopaedic or other conditions. The only available human data are a small case series on knee injections with self-reported pain reduction but serious methodological shortcomings, and a pilot study in just two people following intravenous administration (PMID 41476424, 41490200, 40131143). On this basis, no reliable conclusions can be drawn about efficacy in humans.
Almost nothing is known about safety in humans. The aforementioned pilot study with two participants found no measurable side effects or abnormalities in blood values for the heart, liver, kidneys, thyroid and blood glucose after intravenous doses of 10 and 20 mg. However, with a sample of two individuals, no safety guarantees can be given. The optimal dosage, the appropriate indications, the administration frequency and the treatment duration are all entirely unknown for use in humans (PMID 40131143, 41476424).
In the world of sport, BPC-157 and related peptides such as TB-500, GHK-Cu, ipamorelin and CJC-1295 are used outside regular clinical frameworks. TB-4 and TB-500 are officially banned substances in sport. The literature emphasises that both physicians and athletes should be aware that this type of peptide falls outside regular registration and oversight procedures, with all the uncertainty and risk that entails (PMID 41476424, 41490200).
All available efficacy data come from animal models or cell culture studies. The only human data consist of a case series and a pilot study with n=2. No RCTs or controlled clinical studies in humans are available.